These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 12677891)
1. [Indications for treatment in invasive ductal carcinoma of the breast with Herceptin from the aspect of laboratory diagnosis--study of the ERBB-2 protein and determination of the number of copies of the ERBB2 gene. Review]. Mrhalová M; Kodet R Cesk Patol; 2002; 38 Suppl 1():4-14. PubMed ID: 12677891 [TBL] [Abstract][Full Text] [Related]
2. HER-2 status determination in breast carcinomas. A practical approach. García-Caballero T; Menéndez MD; Vázquez-Boquete A; Gallego R; Forteza J; Fraga M Histol Histopathol; 2006 Mar; 21(3):227-36. PubMed ID: 16372244 [TBL] [Abstract][Full Text] [Related]
3. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964 [TBL] [Abstract][Full Text] [Related]
4. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization. Jimenez RE; Wallis T; Tabasczka P; Visscher DW Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908 [TBL] [Abstract][Full Text] [Related]
5. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number. Mrhalová M; Kodet R; Kalinová M; Hilská I Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261 [TBL] [Abstract][Full Text] [Related]
6. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1. Mrhalova M; Kodet R Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059 [TBL] [Abstract][Full Text] [Related]
7. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice? Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225 [TBL] [Abstract][Full Text] [Related]
8. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer. Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626 [TBL] [Abstract][Full Text] [Related]
9. [Diagnosis of HER2 gene amplification in breast carcinoma]. Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424 [TBL] [Abstract][Full Text] [Related]
10. Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Diaz NM Cancer Control; 2001; 8(5):415-8. PubMed ID: 11579337 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. Lottner C; Schwarz S; Diermeier S; Hartmann A; Knuechel R; Hofstaedter F; Brockhoff G J Pathol; 2005 Apr; 205(5):577-84. PubMed ID: 15732132 [TBL] [Abstract][Full Text] [Related]
13. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma. Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082 [TBL] [Abstract][Full Text] [Related]
14. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. Simon R; Nocito A; Hübscher T; Bucher C; Torhorst J; Schraml P; Bubendorf L; Mihatsch MM; Moch H; Wilber K; Schötzau A; Kononen J; Sauter G J Natl Cancer Inst; 2001 Aug; 93(15):1141-6. PubMed ID: 11481385 [TBL] [Abstract][Full Text] [Related]
15. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Dybdal N; Leiberman G; Anderson S; McCune B; Bajamonde A; Cohen RL; Mass RD; Sanders C; Press MF Breast Cancer Res Treat; 2005 Sep; 93(1):3-11. PubMed ID: 16184453 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of an ERBB2 gene expression signature in breast cancers. Bertucci F; Borie N; Ginestier C; Groulet A; Charafe-Jauffret E; Adélaïde J; Geneix J; Bachelart L; Finetti P; Koki A; Hermitte F; Hassoun J; Debono S; Viens P; Fert V; Jacquemier J; Birnbaum D Oncogene; 2004 Apr; 23(14):2564-75. PubMed ID: 14743203 [TBL] [Abstract][Full Text] [Related]
17. A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system. Mrhalova M; Kodet R J Cancer Res Clin Oncol; 2007 May; 133(5):321-9. PubMed ID: 17165026 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women. Singhai R; Patil V; Patil A Asian Pac J Cancer Prev; 2011; 12(1):179-83. PubMed ID: 21517254 [TBL] [Abstract][Full Text] [Related]
19. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy? Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790 [TBL] [Abstract][Full Text] [Related]
20. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas. Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]